You are here

  • Home
  • Archive
  • Volume 78, Issue 6
  • Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis

Article info

Article menu

This article has a correction. Please see:

Download PDFPDF
Systemic sclerosis
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis

Authors

  1. Correspondence to Dr Mandana Nikpour, Department of Medicine, University of Melbourne, Fitzroy 3065, Victoria, Australia; m.nikpour{at}unimelb.edu.au
View Full Text

Citation

Ferdowsi N, Huq M, Stevens W The Scleroderma Clinical Trials Consortium Damage Index Working Group, The Australian Scleroderma Interest Group, Canadian Scleroderma Research Group, et al
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis
Annals of the Rheumatic Diseases 2019;78:807-816.

Publication history

  • Received November 14, 2018
  • Revised March 11, 2019
  • Accepted March 12, 2019
  • First published March 30, 2019.
Online issue publication 
May 12, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.